HOXA10 and familial pancreatic carcinoma: Higher HOXA10-AS expressions have been linked to shorter survival times in GC (Li et al., 2022), pancreatic cancer (Wu et al., 2022), leukemia (Al-Kershi et al., 2019), OSCC (Wang, 2021; Yan et al., 2020), LUAD (Sheng et al., 2018), LSCC (Zhao et al., 2024), and glioma (Isaev et al., 2021).